Johnson & Johnson ERLEADA — Percent Change (as a percent) increased by 1825.0% to 23.1% in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 94.1%, from 11.9% to 23.1%. This is a positive signal — higher values indicate stronger performance for this metric.
A positive percentage indicates accelerating sales growth, whereas a negative percentage suggests a slowdown in demand or market saturation.
This metric measures the period-over-period percentage growth or decline in net sales for the ERLEADA product line. It s...
Comparable to year-over-year or quarter-over-quarter growth rates for specific blockbuster drugs reported by peer pharmaceutical firms.
jnj_segment_erleada_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 77.6% | 66.7% | 53% | 49.5% | 42.2% | 35.6% | 25.9% | 28.7% | 27% | 29.8% | 25.4% | 11.9% | 23.4% | 18.4% | 1.2% | 23.1% |
| QoQ Change | — | -14.0% | -20.5% | -6.6% | -14.7% | -15.6% | -27.2% | +10.8% | -5.9% | +10.4% | -14.8% | -53.1% | +96.6% | -21.4% | -93.5% | >999% |
| YoY Change | — | — | — | -36.2% | -36.7% | -32.8% | -47.7% | -32.0% | -24.2% | +15.1% | -11.5% | -55.9% | -21.5% | -27.6% | — | +94.1% |